In Vitro and In Vivo Assessment of Dermatophyte Acquired Resistance to Efinaconazole, a Novel Triazole Antifungal | Zendy

Atsushi Iwata | Zendy; Yoko Watanabe | Zendy; Naomichi Kumagai | Zendy; Maria Katafuchi-Nagashima | Zendy; Keita Sugiura | Zendy; Radhakrishnan Pillai | Zendy; Yoshiyuki Tatsumi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro and In Vivo Assessment of Dermatophyte Acquired Resistance to Efinaconazole, a Novel Triazole Antifungal

Author(s) -

Atsushi Iwata,

Yoko Watanabe,

Naomichi Kumagai,

Maria Katafuchi-Nagashima,

Keita Sugiura,

Radhakrishnan Pillai,

Yoshiyuki Tatsumi

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02703-13

Subject(s) - dermatophyte , trichophyton rubrum , trichophyton , drug resistance , in vivo , medicine , antifungal , biology , dermatology , microbiology and biotechnology

Efinaconazole is a novel triazole antifungal drug for the topical treatment of onychomycosis, a nail infection caused mainly by dermatophytes. We assessed the potential of efinaconazole to induce resistance in dermatophytes by continuous exposure of Trichophyton rubrum strains to efinaconazole in vitro (12 passages) and in a guinea pig onychomycosis model (8 weeks). There was no evidence of efinaconazole resistance development in the tested strains under the experimental conditions used.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research